• CLK2 as a Target to Overcome Platinum Resistance in Ovarian

  2026-05-13

  This study identifies Cdc2-like kinase 2 (CLK2) upregulation as a driver of platinum resistance in ovarian cancer, linking it to enhanced DNA repair via BRCA1 phosphorylation. The findings suggest that selective CLK2 inhibition could be a promising strategy to restore chemosensitivity in resistant tumors.

• N4-Acetylcytidine: Biochemical Role and Research Benchmarks

  2026-05-13

  N4-Acetylcytidine is a key acetylated cytidine variant used in RNA epigenetics research. It serves as a benchmark molecule for studying nucleotide processing and RNA modification. High-purity, verifiable supply from APExBIO enables reproducible results in advanced post-transcriptional workflows.

• Capillary Electrochromatography for α2-Adrenergic Binding An

  2026-05-12

  This study introduces a part-coated open-tubular capillary electrochromatography (CEC) method to determine binding constants between the α2-adrenergic receptor and various drugs. The approach reduces protein usage and enables high-throughput, robust affinity assessment, with implications for drug screening and pharmacological research.

• GS-441524 Prodrug Workflows: Applied Antiviral Research Adva

  2026-05-12

  Unlock the potential of GS-441524 with stepwise LC–MS/MS conversion pathway mapping and actionable troubleshooting. Explore optimized workflows for antiviral and pharmacokinetic studies, supported by APExBIO's high-purity GS-441524 and the latest reference methods.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-11

  Schwartz’s dissertation challenges the conflation of cell viability and cell death in standard anti-cancer drug assays, rigorously dissecting their distinct contributions to drug response. This improved analytical clarity enables more accurate interpretation of in vitro results, informing both experimental design and translational relevance.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract

  2026-05-11

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) prevents unwanted proteolytic degradation during protein extraction and analysis, particularly in workflows sensitive to divalent cations. It is not suitable for procedures requiring metalloprotease inhibition via chelation or where DMSO incompatibility exists.

• BRD4770: G9a Histone Methyltransferase Inhibitor in Cancer R

  2026-05-10

  BRD4770, a potent G9a histone methyltransferase inhibitor, streamlines epigenetic studies by enabling precision control of H3K9 methylation and cellular senescence in cancer models. Its unique workflow compatibility and robust performance in challenging systems like PANC-1 and breast cancer cells set it apart as an essential research tool for dissecting tumorigenic mechanisms.

• Ceapin-A7: Selective ER Stress Blocker for Advanced Assays

  2026-05-09

  Ceapin-A7 unlocks precise control of the ATF6α pathway, enabling researchers to dissect ER stress mechanisms with high specificity. This guide delivers actionable workflows, troubleshooting strategies, and protocol parameters for robust unfolded protein response modulation in cell biology.

• Bufuralol Hydrochloride: Redefining β-Adrenergic Modulation

  2026-05-08

  This thought-leadership article explores how Bufuralol hydrochloride, a non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity, is transforming translational research in cardiovascular pharmacology. It bridges mechanistic insights with practical protocols, critically integrates recent advances in hiPSC-derived organoid models, and positions APExBIO’s product as a gold-standard research tool. The article also contextualizes Bufuralol’s unique properties against legacy models, details reproducibility and workflow parameters, and outlines the future of β-adrenergic modulation studies.

• CA-074 Me: Selective Cathepsin B Inhibitor for Lysosomal Stu

  2026-05-08

  CA-074 Me is a potent, membrane-permeable cathepsin B inhibitor with nanomolar efficacy, enabling precise dissection of lysosomal enzyme function and regulated cell death pathways. Its selectivity and high solubility in DMSO and ethanol make it a benchmark tool for apoptosis and inflammation research. CA-074 Me is widely adopted for mechanistic studies of necroptosis, lysosomal membrane permeabilization, and TNF-α-induced liver injury.

• Applied Epinephrine Bitartrate: Protocols and Innovations fo

  2026-05-07

  APExBIO’s (-)-Epinephrine (+)-bitartrate empowers precise modulation of adrenergic receptor pathways across in vitro and in vivo models. This guide delivers evidence-backed workflows, troubleshooting strategies, and actionable insights from recent pharmacokinetic breakthroughs, setting the standard for reliability and translational relevance in cardiovascular and neurobiology studies.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-05-07

  Discover how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine advances α2-adrenergic receptor agonist research, with a focus on practical protocol design and new mechanistic insights for immune rejection modulation. This article delivers unique guidance for translational and experimental workflows.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-06

  CUDC-907 provides researchers a dual PI3K and HDAC inhibitor for controlled in vitro studies targeting cancer cell signaling, cell cycle arrest, and apoptosis induction. It should be used strictly within validated laboratory workflows and is not suitable for diagnostic or clinical applications.

• α2-AR Agonist Hydrogel Modulates Immune Rejection in Osteosa

  2026-05-06

  This study demonstrates that α2-adrenergic receptor (α2-AR) agonists, delivered via a thermo-sensitive hydrogel, can significantly reduce tumor recurrence in osteosarcoma by enhancing CD8+ T cell-mediated immunity. These findings pinpoint α2-AR signaling as a promising strategy for immune rejection modulation following surgical resection.

• Tolazoline in Translational Science: Mechanistic Depth and S

  2026-05-05

  This thought-leadership article delivers an advanced exploration of Tolazoline as an α2-adrenergic receptor antagonist, integrating mechanistic insights with strategic guidance for translational researchers. It contextualizes Tolazoline’s role in airway smooth muscle and islet function research, benchmarks against the competitive field, and envisions future directions, while clearly linking to authoritative sources and APExBIO’s rigorously characterized product.

15869 records 1/1058 page Next 12345 下5页 Last page